1. Stratégie de vaccination contre le SARS-CoV-2 – Place du vaccin à ARNm COMIRNATY® (BNT162b2). Haute Autorité de Santé n.d. https://www.has-sante.fr/jcms/p_3227132/fr/strategie-de-vaccination-contre-le-sars-cov-2-place-du-vaccin-a-arnm-comirnaty-bnt162b2 (accessed March 3, 2021).
2. BioNTech SE. A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS. clinicaltrials.gov; 2021.
3. Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine | CDC 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html (accessed March 3, 2021).
4. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates;Walsh;N Engl J Med,2020
5. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020